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Abstract 
 
BACKGROUND: Despite oral antiplatelet treatment a certain number of patients suffer 
adverse events while on therapy. Whether patients demonstrating low platelet inhibition in 
vitro are at increased risk for adverse events is unknown. The prevalence of clopidogrel 
resistance ranges from 4-60% in the literature and a standardized cut off value for 
determining resistance, protocol for treatment and testing is lacking. Characteristics of the 
clopidogrel resistant patient are unknown.  
 
OBJECTIVES: The aim of the study was to determine a comparable, clinically applicable 
reference cut-off value for clopidogrel resistance with the VASP method in patients with 
coronary artery disease (CAD). Furthermore we sought to explore the prevalence of 
resistance in the same population while on clopidogrel treatment, and within defined 
patient sub-groups. 
 
METHODS: Vasodilator-stimulated phosphoprotein (VASP) analyses, a standardized flow 
cytometric assay which yields a VASP platelet reactivity index (PRI) value indicating residual 
platelet activity, were performed on whole blood samples from 158 patients with 
angiographically documented CAD on clopidogrel treatment. The cut-off value for resistance 
was defined by the 5%-percentile in a control group of patients with CAD (n=105) being on 
aspirin.  
 
RESULTS: The cut-off value for clopidogrel resistance was determined to be VASP PRI  55. 
29.7% of the patients had a VASP PRI 55 while on clopidogrel treatment. We did not find 
any correlation between clopidogrel resistance and age (r=0.005, p=0.952). There were also 
no associations with gender (p=0.596), smoking habit (p=0.523), hypertension (p=0.445) or 
diabetes (0.498).  
 
CONCLUSIONS: VASP analysis could be useful for monitoring response to treatment and 
tailoring antithrombotic drug regimens for CAD patients. This would be of great importance 
if future prospective clinical studies show that clopidogrel resistant patients are at higher 
risk for adverse events than patients with an acceptable platelet inhibition with clopidogrel.  
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Background 
The antithrombotic anti-platelet agents aspirin and clopidogrel are widely used when 
treating patients with atherotrombotic disease in cardiovascular or other vascular beds. 
Administrated alone or in combination, both have proven efficacy when it comes to reducing 
the risk of adverse events, such as myocardial infarction, stroke or vascular death (1). The 
results of the CAPRIE study showed clopidogrel to be superior to aspirin (p=0.043) in 
reducing the risk of ischaemic stroke, myocardial infarction and vascular death (2) and in the 
CURE study the benefit of adding clopidogrel to aspirin treatment was demonstrated (dual 
therapy was more effective than aspirin and placebo) (3). The ongoing ASpirin- and 
Clopidogrel non-responsiveness clinical Endpoint Trial (ASCET) will explore whether 
clopidogrel can improve the clinical outcome during a two year follow-up in  patients with 
coronary artery disease (CAD) with low initial response to aspirin in laboratory tests (4).  
The thienopyridine clopidogrel acts by blocking adenosine diphosphate (ADP)-
dependent aggregation of platelets. ADP is obligate for the release of more ADP from 
platelet granula which reinforces the aggregation induced by ADP itself or its agonists. 
Furthermore ADP mediates down-regulation of the adenylyl cyclase in the platelet, thus 
decreasing cyclic adenosine monophosphate (cAMP) production and facilitating platelet 
activation and aggregation. Clopidogrel is a pro-drug, converted to its active metabolite, a 
thiol derivate, through oxidation and hydrolysis by hepatic CYP450 isoenzymes. The active 
form binds selectively and irreversibly to one of the two ADP-receptors of the platelet; 
P2Y12 and P2Y1. P2Y12 is a 7-transmembrane receptor coupled to a Gi-protein that triggers 
multiple cellular pathways when stimulated (5). Dephosphorylation of the intracellular 
vasodilator-stimulated phosphoprotein (VASP) is dependent on P2Y12-receptor stimulation. 
Inhibition of P2Y12 by clopidogrel induce phosphorylation of VASP by c-AMP-dependent 
protein kinases. A low level of VASP-phosphorylation therefore reflects receptor activation, 
while high levels of phosphorylated VASP reflect P2Y12 inhibition (6). This can therefore be 
used to measure the degree of platelet inhibition. 
Despite oral antiplatelet treatment a certain number of patients suffer myocardial 
infarction, stroke or vascular death while on therapy, formerly named “clinical resistance” or 
“treatment failure”. A likely hypothesis is that incomplete platelet inhibition is the main 
cause. Despite the use of anti-platelet agents, laboratory methods have showed that some 
patients fail to achieve the expected level of platelet inhibition and demonstrate a high 
platelet residual activity, i.e. “laboratory resistance”. In vitro analysis have revealed that 
patients on clopidogrel demonstrates a significantly lower platelet activity than volunteers 
and patients not receiving clopidogrel (p<0.0001)(6). However the wider range of values and 
a larger standard deviation in this group demonstrates a great interindividual variability in 
the response to clopidogrel, which otherwise follows a normal bell-shaped distribution (7,3). 
We will use the term “resistance” as recommended by the European Society of Cardiology 
Working Group on Thrombosis, describing a state where in vitro platelet reactivity is not 
adequately blocked by oral antiplatelet agents (1). Some studies have been able to show a 
link between laboratory findings and clinical outcome in patients, and in recent small, clinical 
studies laboratory findings of clopidogrel resistance seem promising as predictors of clinical 
outcome (1,8, 9).  
A number of mechanisms have been proposed to explain the great interindividual 
variability in the response to clopidogrel. These include patient non-compliance and failure 
to prescribe the right dosage, poor absorption of the drug, drug-drug interactions 
(demonstrated for some statins and clopidogrel), differences in metabolic activity and 
genetic polymorphisms of the CYP system, platelet variation (life span, ADP volume released, 
ADP-receptor (P2Y1 and P2Y12) up-and down-regulation) and platelet activation by 
alternative pathways (10,11). 
 Measuring ADP-induced maximum platelet aggragtion by light tranmittance 
aggregometry (LTA), Verify Now and flow-cytometric-based VASP assay are some of the 
methods that have been applied to detect clopidogrel resistance.  Aleil et al showed that 
flow cytometric VASP phosphorylation state is highly correlated with specific inhibition of 
P2Y12 - the target receptor for clopidogrel (r=0,72 and p<0,0001) (6). Further advantages of 
the VASP assay, is that it requires a low sample volume, it can be used with whole blood and 
it is stable for about 72 h (12). From flow-cytometric analysis and fluorescence 
measurements of blood samples incubated with natural agonists and antagonists of platelet 
aggregation and activation (PGE1 and ADP), a platelet reactivity index (PRI) can be 
calculated, expressed as a percentage value (100% equals full reactivity, i.e. no inhibition of 
platelets).  
In the beforementioned study, Aleil et al found, as expected, that patients receiving 
clopidogrel had significantly lower PRI than healthy blood donors (volunteers) and patients 
not on clopidogrel. However, approximately 33% of the patients receiving clopidogrel had a 
PRI equivalent to that of patients not under clopidogrel treatment, i.e. as if they were not on 
treatment (6).   
Clinical studies exploring resistance to clopidogrel are now numerous, but with the 
prevalence of resistance ranging from 4-60% (14).  
The aim of the present study was to determine a comparable and clinically applicable 
reference cut-off value for clopidogrel resistance with the VASP method in patients with 
stable CAD from the ASCET-population (4). Furthermore we sought to explore the 
prevalence of this phenomenon in the same population while on clopidogrel treatment, and 
within defined patient sub-groups. 
 
 
 
 
Methods 
Study population 
The patients included in this project were all participating in the ASCET study which was 
mainly aimed at investigating the influence of non-responsiveness to aspirin treatment on 
clinical events.  They were 18-80 years of age, of either gender and had angiographically 
documented CAD being treated with aspirin 160 mg/d for at least one week before inclusion, 
treated with angioplasty/stent implantation (percutaneous coronary intervention (PCI)) or 
not. The exclusion criteria were indication for warfarin treatment, contraindications to 
aspirin or clopidogrel, malignancy that might interfere with life expectancy, psychiatric 
disease, mental retardation, dementia, drug abuse, alcoholism or conditions thought to 
reduce compliance. The patients were randomized to either continued aspirin treatment or 
to clopidogrel 75 mg/d (tablets of Plavix® (Sanofi Winthrop Industries, Ambarese, France and 
Bristol-Myers Squibb SNC, Paris, France)). The medications were covered by the Act of 
National Insurance Administration. The study was approved by the Regional Ethics 
Committee and all patients have given written informed consent to participate.  
The present investigation was performed in 158 randomly selected patients one month after 
being randomized to treatment with clopidogrel. In addition we included 105 patients on 
aspirin for determination of the cut-off level for the VASP method.  
 
Blood samples 
Blood samples for testing platelet reactivity were drawn in fasting condition in the morning 
before administration of any medication, i.e. about 24 hours after the last dose of 
clopidogrel. Blood was collected in vacutainer tubes containing citrate (0.129M in dilution 
1:10). Samples were kept at room temperature and analyzed within 48 hours. 
 
Laboratory method: VASP phosphorylation 
The effect of clopidogrel on platelet function was evaluated in vitro with the analysis of 
VASP. VASP is an intracellular protein in platelets, which is dephosphorylated in the normal 
state. Phosphorylation of VASP is regulated by the cAMP cascade. PGE1 activates this 
cascade, while the cascade is inhibited by ADP via the P2Y12 receptor (Fig. 1). 
  
 
Figure 1: Phosphorylation state of VASP indicates state of platelet activation. PGE1 inhibits platelets, while ADP 
inhibits the inhibitor. The cAMP cascade is not shown.  
 
To determine the VASP phosphorylation state of whole blood, we used a standardized flow 
cytometric assay [PLT VASP/P2Y12;Biocytex, Marseille, France]. Citrated blood samples were 
incubated with PGE1(10 µm) alone or with PGE1 and ADP simultaneously (10 µm) for 10 
minutes. Samples were then fixed and the cells permeabilized. Immunolabelling was done 
using indirect no wash immunofluorescence primary anti VASP-P mouse monoclonal 
antibody, followed by a secondary fluorescein and polyclonal antibody anti mouse IgG-FITC. 
Platelet counter-staining reagent-PE (anti CD61-PE) was also used. The duration of the 
preparation of samples did not exceed 30 minutes, as recommended by the supplier. 
Analyses were performed on a FACSCalibur flow cytometer (Becton Dickinson, USA) and 
platelet populations were identified using forward and side scatter. 
A platelet reactivity index (PRI) was calculated using corrected (by negative control) mean 
fluorenscence intensity of samples incubated with PGE1 or PGE1 and ADP according to this 
calculation: 
PRI =  [(MFIC PGE1 – MFIC (PGE1+ADP) / MFIC PGE1] x 100 
 
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD) and categorical 
variables are presented as frequencies and percentages.  
PGE1 
Inhibited 
platelets 
Normal state 
platelets, can 
be activated 
VASP-P VASP 
ADP 
Clopidogrel 
 
Comparisons between groups were performed by independent-samples t-tests or Mann-
Whitney test for continuous variables and chi-square exact test for categorical variables. 
Coefficient of correlation was calculated by Pearson. P<0.05 was considered statistically 
significant. Statistical analysis was performed using SPSS (v16.0, SPSS Inc).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
The demographic and clinical characteristics of the total ASCET population are given in  
Table 1.  
 
 
Table 1: Characteristics of the CAD population (n=1001). Values are mean (SD) or number (proportions) if not 
otherwise stated. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ACE:  
angiotensin converting enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our sub-study population 124 patients were men (78%) and 34 (22%) women. The number 
of hypertensives was 94 (59.4%), 27 (17%) were diabetics and 24 (15%) current smokers. 
With these numbers we find this sub-population to be representative for the whole ASCET 
population. 
 
 
Men/Women (%)  783/218 (78/22) 
Diabetes Mellitus n (%) 200 (20) 
Myocardial infarction n (%) 436 (44) 
Hypertension n (%) 553 (56) 
SBP (mmHg) 139.4 (19.3) 
DBP (mmHg) 82.1 (9.7) 
Current smokers n (%) 204 (20.4)  
BMI (kg/m2) 27.9 (11.5) 
Total cholesterol (mmol/l) 4.6 (1.0) 
HDL cholesterol  (mmol/l) 1.3 (0.4) 
LDL cholesterol  (mmol/l) 2.5 (0.8) 
Triglycerides  (mmol/l) 1.6 (1.1) 
Fasting glucose (mmol/l) 6.0 (1.9) 
HbA1c (%) 6.0 (0.9) 
Medication %  
 Statins   98 
 Aspirin 100 
 β-Blockers   76 
 Nitrates   22 
 ACE inhibitors   26 
Determination of cut-off value 
To determine the cut off-value for clopidogrel resistance in our study population we used a 
control group of 105 CAD patients also from the ASCET population. The control group had 
received aspirin 160 mg/d for at least one week when their blood was drawn to obtain VASP 
PRI. Aspirin is a COX-inhibitor, inhibiting platelet activation by another route than clopidogrel 
does. Aspirin is not known to have any interaction with the P2Y12-receptor, so we consider 
the VASP PRI obtained in this group to be similar to “normal” VASP PRI values in CAD 
patients.  
 
VASP PRI in the control group (n=105) (Fig. 2) showed a somewhat skew and broad 
distribution with a mean of 82.6 +/- 12.4. The minimum was 18.0 and the maximum 96.0. 
The 5% percentile was 54.8, and  55 was chosen as the cut-off value for clopidogrel 
resistance in our study population. 
 
 
  
 
Figure 2: VASP PRI distribution (82.6 +/- 12.4) of a group of 105 CAD patients not receiving P2Y12 antagonist.  
5% percentile 
 
Prevalence of resistant patients 
 
The distribution of VASP PRI in the patients on clopidogrel treatment (n=158) gave a mean 
VASP PRI of 42.0, compared to 82.6 in the control group (p<0.001 (t-test); p<0.001 (Mann-
Whitney test). The SD and range were also wider (21.0 vs 12.4) in this group, indicating the 
expected large interindividual variation in response to clopidogrel (Fig.3).  
 
The VASP PRI in the study group is almost normally distributed, more so than in the control 
group. Such a distribution permitted the further use of parametric statistical methods in the 
study when performing analyses on the clopidogrel-treated group alone.   
 
 
 
 
 
 
Figure 3: VASP PRI distribution (42.0± 21.0) in patients (n=158) receiving 75 mg Plavix® daily. As also denoted in 
other literature, the response to clopidogrel is normally distributed and bellshaped (7,3). Patients with a VASP 
PRI  55 are to be characterized as resistant to clopidogrel in our study. 
 
 
Using the defined cut-off value of VASP PRI  55 for clopidogrel resistance, 29.7% of the 
patients (47/158) were classified as resistant. (Table 2). 
RESPGR 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 0 47 29.7 29.7 29.7 
1 111 70.3 70.3 100.0 
Total 158 100.0 100.0  
Table 2: Frequency of resistant patients. Patients with PRI VASP  55 in group “0” (non-responder).  
 
 
 
VASP-PRI levels within defined sub-groups of patients  
 
VASP PRI levels showed no significant correlation with age ((r=0.005; p=0.952) Figure 4). 
There were also no difference in VASP PRI when comparing the 10% youngest (age ≤51 yrs) 
and the 10% oldest of patients (age> 76 yrs)( 44±27 vs. 47±17;p=0.670). When divided into 
quartiles, comparing the 25% youngest and oldest, the p value was 0.925. 
 
 
 
Figure 4: Correlation between VASP PRI and age. 
 
There was no statistically significant difference in VASP PRI levels between men and women 
(43±22 vs 36±18; p=0.067). Nor were there any differences between groups of smokers and 
non-smokers (42±24 vs. 42±21; p=0.957) (Table 3a and b), hypertensive versus non-
hypertensive  patients (43±20vs.40±22; p=0.421) or diabetic versus non-diabetic patients 
(42±22 vs. 42±21; p=0.907). 
 
 
Table 3a and 3b:  Tables showing independent samples t-test for comparing means of PRI VASP between 
smokers and non-smokers, as an example of calculation.  
 
 
a) 
Group Statistics 
 SMOKE1 N Mean Std. Deviation Std. Error Mean 
VASPPRI2 0 134 42.0653 20.65009 1.78390 
1 24 41.8129 23.51971 4.80094 
 
 
b) 
Independent Samples Test 
  Levene's Test for 
Equality of Variances t-test for Equality of Means 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
  Lower Upper 
VASPPRI2 Equal variances 
assumed 
.324 .570 .054 156 .957 .25238 4.67634 -8.98473 9.48950 
Equal variances 
not assumed 
  
.049 29.692 .961 .25238 5.12165 -10.21199 10.71675 
 
 
 
 
Clopidogrel resistance according to the defined cut-off value in subgroups of patients 
The number of resistant patients did not differ significantly between any of the groups, 
shown in Tables 4 and 5, and Figure 4. 
 
Table 4: Number of patients being resistant/responders in subgroups of patients 
 Resistant patients Responders p 
Male 42 82 0.596 
Female 5 29  
    
Smokers 7 17 0.523 
Non-smokers 40 94  
    
Diabetic 9 18 0.498 
Non-diabetic 38 93  
    
Hypertensive 28 66 0.445 
Non-hypertensive 19 45  
 
 
Figure 5: Number of clopidogel resistant patients within different patient groups.  
 
Table 5: Chi-square test to calculate the equality of number of resistant (population proportions) in 
diabetic/non-diabetic patients, as an example of statistical calculation. Patients are grouped as either 
responders or clopidogrel resistant within their diabetic/non-diabetic group. 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 1.474E2 148 .498 
Likelihood Ratio 136.185 148 .748 
Linear-by-Linear Association .014 1 .906 
N of Valid Cases 158   
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Discussion 
 
In this study we defined resistance to clopidogrel according to the VASP PRI range in 
a control group of patients with angiographically documented CAD not receiving clopidogrel. 
The 5% percentile of this group was VASP PRI 55. Of the patients in the study population 
29.7% had a VASP PRI equivalent or superior to this, i.e. were resistant.  
This is in line with the results from Aleil et al, who also explored clopidogrel effect by VASP 
analyses and found that 33% of their patients with cardiovascular disease on clopidogrel 
treatment had a PRI equivalent to values in patients not on clopidogrel treatment (6). 
The prevalence of clopidogrel resistance ranges from 4-60% (14) in different studies. 
An explanation for this wide range could be the many differences in study protocols applied. 
For example the dosage of clopidogrel varies (there is controversy in the literature on what 
is the most efficient dosage). There are also different methods of measurement, differences 
in patient populations, relatively small patient populations in the studies overall, different 
time for platelet evaluation in relation to time of administration of drug and lastly there is no 
univocal definition on how resistance should be defined, in terms of either a certain numeric 
cut-off value, a cut-off value defined for the population studied based on platelet in-vitro 
analysis or others. 
In our study, VASP PRI levels did not show any associations with age, sex, smoking, 
hypertension or diabetes. We did not find that the frequency of clopidogrel resistance was 
significantly higher within any of these subgroups of patients.  
Angiolillo et al reported, contrary to what we found, the there were a higher number 
of clopidogrel resistant patients within a group of diabetic subjects compared to non-
diabetic individuals (p=0.04). Overall ADP-induced platelet aggregation and platelet 
activation was also higher in diabetic than in non-diabetic patient in their study (15). In their 
study resistance was defined as an absolute reduction of <10 in platelet aggregation with 
ADP 24 h after 300 mg clopidogrel administration compared with baseline values. Patients in 
this study did also receive aspirin, thus the intervention group had dual therapy with 
clopidogrel.  
 
There are currently no results available from large clinical prospective randomized 
trials studying whether clopidogrel resistant patients have a higher rate of adverse events or 
increased risk of death compared to clopidogrel responders. The data available are mainly 
observations of patients with different acute coronary syndromes (ACS).  
Some of the first to explore this, Matetzky et al, found that in their patient group of 
STEMI-patients undergoing PCI, 40% of patients exhibiting the highest quartile of ADP-
induced aggregation while on clopidogrel treatment, experienced a recurrent cardiovascular 
event within six months. In the two quartiles with the lowest aggregation values none of the 
patients experienced such events (16). 
Frere et al followed patients having undergone PCI for NSTE ACS (non-ST elevating 
myocardial infarction acute coronary syndrome) for one month. They found that VASP PRI 
was significantly lower in patients who did not experience cardiovascular events, than in 
those who did. The cut off value for detecting patients at higher risk for events was 53 in 
their material, determined by ROC curve analyses. This yielded VASP PRI a negative 
predictive value of 99%. (9). A negative predictive value of 100% for VASP PRI was found for 
excluding major adverse cardiovascular event (MACE) after PCI in patients with NSTE ACS, 
stable angina pectoris and/or silent ischemia by Bonello et al in 2007 (13). Their ROC analysis 
showed an optimal cut-off of VASP PRI 50. These cut-off values, based on patient 
observations, fit well with our statistically defined cut-off (VASP PRI 55) based on our 
control group of CAD patients on aspirin.  
Clinical prospective randomized controlled trials are needed to determine if 
clopidogrel resistant patients have a higher rate of adverse events or increased risk of death 
compared to clopidogrel responders.  
It has been suggested that the risk of bleeding and protection from MACE is not 
correlated with the P2Y12-antagonist used, but rather the degree of platelet inhibition 
achieved. Should this be true, a VASP PRI cut-off value should be valid for all thienopyridines 
(5). Thus, despite new thienopridines on the horizon, characterized by faster onset of action 
and more consistent inhibition, research on clopidogrel, which still maintains the position as 
the most widely used and safest drug, is not in vain. The importance of agreeing on a study 
protocol for obtaining comparable results when discussing prevalence of resistance to 
thienopyridines in different patient populations cannot be emphazised strongly enough. 
 
Our data showed that clopidogrel response varies substancially interindividually, as 
described elsewhere (7). The mechanisms for clopidogrel resistance is not fully defined and 
known, but several hypotheses have been presented. 
Patient non-compliance should always be thought of. In the case of clopidogrel, 
inappropriate timing for measuring effect or inappropriate dosing seems more likely as a 
cause of resistance. As mentioned, there is controversy regarding the optimal loading and 
maintenance dose of clopidogrel. Aleil et al demonstrated that resistance to clopidogrel is 
dose-related. In their study of 153 elective PCI-patients the proportion of low responders  
(VASP PRI≥69, on basis of their previous study (6))  was significantly lower in patients 
randomized to clopidogrel 150 mg/day than in those randomized to clopidogrel 75 mg/day 
(8.6% vs. 33.7%; p = 0.0004).  In the clopidogrel 75 mg/day group, 64.5% of low responders 
became responders after switching to clopidogrel 150 mg/day for 2 weeks (17). 
 In 2008 Bonello et al (8) evaluated the clinical impact of adjusting the loading dose of 
clopidogrel according to the VASP index in patients with clopidogrel resistance undergoing 
PCI. Clopidogrel resistance was defined as a VASP >50% after a 600-mg loading dose. 
Patients with clopidogrel resistance undergoing coronary stenting were randomized to a 
control group or to a VASP-guided group, in which patients received additional doses of 
clopidogrel to decrease the VASP PRI below 50. Dose adjustment was efficient in 86% of 
patients and VASP index was significantly decreased (p < 0.001). The rate of major adverse 
cardiac events was significantly lower in the VASP-guided group (p = 0.007). In 2009 they 
performed a similar study on a larger patient population, with similar results (18). 
Further mechanisms for resistance encompasses reduced bioavailability of 
clopidogrel, either because of poor absorption from the intestine (19), decreased or initially 
low hepatic conversion to the active metabolite or drug-drug interaction at the enzymatic 
level. The metabolism of clopidogrel is dependent on the hepatic cytochrome 450 
isoenzymes (CYP3A4, CYP2C19, CYP1A2, CYP2B6 and CYP2C9)(20).   
Wide interindividual variability in CYP3A4 activity has been demonstrated in both 
patients and healthy volunteers. Percent platelet aggregation in patients after clopidogrel 
administration correlated inversely with CYP3A4 activity (r=-0.6, p=0.003). They also noted 
improvement of platelet inhibition in subjects initially resistant to clopidogrel with 
coadministration of rifampicin (inducer of CYP3A4) (19).  
CYP3A4 enzymes metabolize as much as one half of drugs prescribed (21). Especially 
statins have been investigated regarding an eventual drug-drug inhibitory interaction with 
clopidogrel, but without univocal results. In the ASCET study 98% of patients received statins 
during the trial. Statins, at least alone, seems not to cause resistance. On the other hand 
St.Johns wort, a herbal supplementation, has been noted to convert clopidogrel non-
responders to responders, by significant induction of CYP3A4 enzymatic activity (21). 
As for CYP2C19, at least 25 different single nucleotide polymorphisms in its coding 
gene have been identified. A significant reduction in serum concentration of the active 
metabolite of clopidogrel and reduced platelet aggregation are associated with the most 
common of these polymorphisms, the CYP2C19*2 in exon 5. This polymorphism has 
therefore been called the “loss-of-function” allele (20, 22). Another study on a 
subpopulation of the ASCET population found that 29% of patients were carriers of the 
CYP2C19*2 polymorphism. In this subpopulation, as in this study, 29% of patients were 
clopidogrel resistant when analyzed with VASP. The frequency of clopidogrel resistance in 
patients with the polymorphism was 46% compared to 22% in wild-type patients (p=0.003). 
A higher prevalence of resistance was found in patients with prior myocardial infarction 
(p=0.001) and interestingly also in patients with a BMI above median (27kg/m2) (p=0.015) 
(23). There is otherwise controversy in the literature on the impact of BMI on clopidogrel 
response.   
  
 When looking for other mechanisms possibly contributing to resistance, it`s 
important to keep in mind the platelets themselves. An increased platelet turnover, as seen 
after surgery, trauma and during infection and inflammation, for example, or diseases 
interfering with the life span of platelets, might have an impact on the effect of clopidogrel 
in the organism. The amount of ADP released by a platelet when activated might also play a 
role. Lastly ADP-receptor (P2Y1 and P2Y12) up-and down-regulation and platelet activation 
by alternate pathways (10, 11) should be considered. Receptor polymorphism has been 
demonstrated for the P2Y12 receptor, although the effect or lack thereof on modulating 
platelet response to clopidogrel is controversial (21). If platelet activation in a patient is for a 
large part mediated by other agonists than ADP and other routes than P2Y12, unsatisfactory 
inhibitory effect of clopidogrel would be likely. 
In the VASP-guided group of Bonello et al`s 2008 study (8), 14.4% of patients 
maintained a PRI>50, even after having received as much as four doses, 2400 mg, of 
clopidogrel. In a recent review, insufficient metabolite generation as the primary explanation 
for nonresponsiveness to clopidogrel, rather than genetic polymorphisms of platelet 
receptors or intracellular signaling mechanisms was discussed (14). In patients who remain 
resistant and demonstrate high platelet activity despite high doses of clopidogrel, on the 
other hand, they suggest that the cause is genetic polymorphism (14). There might thus not 
be only one mechanism for clopidogrel resistance.  
 
 
In summary 
The VASP method has so far been used only for research purposes, but in vitro 
evaluation of platelet inhibition to identify non-responders or resistant patients on 
antiplatelet agents might very well be the future of clinical practice. The ongoing ASCET 
study, the first large prospective study on aspirin non-responsiveness, will show whether 
aspririn non-responders according to laboratory testing, are at higher risk for adverse events 
than patients with acceptable response to aspirin. Similar prospective studies on clopidogrel 
are needed in the future. Should such results indicate that resistant patients have a higher 
rate of adverse events or increased risk of death compared to clopidogrel-respondant 
patients, VASP PRI evaluation could be used by the physician to determine whether a patient 
should receive clopidogrel or if another antiplatelet drug would give more optimal platelet 
inhibition. 
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